NCT04156867 is a NA clinical trial of Dynesys in Orthopedic Disorder of Spine, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT04156867?

NCT04156867 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT04156867?

Interventions in NCT04156867: Dynesys.

What condition does NCT04156867 study?

NCT04156867 studies Orthopedic Disorder of Spine.

Is NCT04156867 still recruiting?

NCT04156867 is currently completed. Last updated 8 November 2019.

Last reviewed 2019-11-08 · How we verify

NCT04156867

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Outcomes of Discectomy With Dynesys in Treatment of Lumbar Disc Herniation

Completed NA Last updated 8 November 2019

What this trial tests

NA trial testing Dynesys in Orthopedic Disorder of Spine in 128 participants. Completed in 1 March 2018.

Timeline

1 August 2014

Primary endpoint
31 December 2017

1 March 2018

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	128
Start date	1 August 2014
Primary completion	31 December 2017
Estimated completion	1 March 2018

Drugs / interventions tested

Dynesys

Conditions studied

Orthopedic Disorder of Spine — all drugs for Orthopedic Disorder of Spine →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 35 to 60, any sex, with Orthopedic Disorder of Spine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the clinical outcomes of discectomy with dynamic neutralization system(Dynesys) on treatment of single-segmental lumbar disc herniation(LDH) versus simple discectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04156867 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 8 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing